Vertex Pharmaceuticals (VRTX) Non-Current Deferred Tax Liability (2009 - 2018)

Vertex Pharmaceuticals has reported Non-Current Deferred Tax Liability for 10 years, with the latest figure at $9.4 million in Q3 2018.

• For the quarter ending Q3 2018, Non-Current Deferred Tax Liability fell 11.87% year-over-year to $9.4 million; the trailing twelve-month figure through Sep 2018 stood at $9.4 million (down 11.87% YoY), and the FY2017 full-year result was $5.5 million, down 95.87% from the prior year.
• Non-Current Deferred Tax Liability for Q3 2018 stood at $9.4 million, up from $9.3 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $136.6 million in Q2 2017, with the low at $5.5 million in Q4 2017.
• Average Non-Current Deferred Tax Liability over 5 years is $74.5 million, with a median of $111.2 million recorded in 2015.
• Year-over-year, Non-Current Deferred Tax Liability soared 853.6% in 2015 and tumbled 95.87% in 2017.
• Tracing VRTX's Non-Current Deferred Tax Liability over 5 years: stood at $11.5 million in 2014, then soared by 853.6% to $110.1 million in 2015, then climbed by 21.48% to $133.7 million in 2016, then plunged by 95.87% to $5.5 million in 2017, then jumped by 70.61% to $9.4 million in 2018.
• The last three Non-Current Deferred Tax Liability figures came in at $9.4 million (Q3 2018), $9.3 million (Q2 2018), and $9.6 million (Q1 2018), per Business Quant data.

Peer Comparison